Thursday, April 10, 2008

Hemostasis LLC

Minneapolis based Hemostasis LLC has a technology very similar to Medafor Inc.'s Arista although it is unclear which applications or countries their products are approved for? The company website says the company............. "designs and manufactures advanced Natural Clotting Polymers (NCP™) and applicators for the treatment of severe externally bleeding lacerations for first aid kits, military, civilian and emergeny room trauma. Combined disciplines of R&D experience from our MTRC™ (Medical Technology Research Center) within the medical device industry, have developed an advanced, biocompatible, natural biopolymer which revolutionizes the way hemorrhaging is treated.
Hemostasis LLC's; BleedArrest™ CP (Clotting Powder) and BleedArrest™ CF (Clotting Foam) are two new hemorrhaging and bleeding control technologies that are changing the way medical professionals are stopping bleeding in seconds. "
Their website does not disclose a lot of information, I will update as further news becomes available.
Patent info is available HERE and HERE and the 510k from the FDA HERE

Haemacure Reveals Positive Results Of Preclinical Study Of Fibrin Sealant In Adhesion Prevention

Haemacure Corp. (HAE.TO) on Thursday revealed the results of a preclinical study it recently conducted on the use of its proprietary lead product candidate, the human fibrin sealant HemaseelHMN, in preventing the formation of post-surgical adhesions. In preclinical testing, Hameacure's fibrin sealant was found to be significantly superior to the control group in preventing the formation of post-surgical tissue adhesion. It was also found to be superior to historical data disclosed in published literature for GYNECARE INTERCEED Absorbable Adhesion Barrier, marketed by Ethicon, Inc. The company said the preclinical results are strategically significant as Haemacure's current fibrin sealant haemostasis formulation was used in this study. Initial analysis indicates that no change in the formulation or the manufacturing of Haemacure's fibrin sealant would be required to pursue an adhesion prevention indication. The company noted that the U.S. market for adhesion prevention products is estimated currently at $100 million and is expected to grow to US$150-200 milion in fibrin sales.